Tamer I. Khayal Sells 3,142 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

Posted by Caroline Horne on Jan 25th, 2023

TransMedics Group, Inc. (NASDAQ:TMDX – Get Rating) insider Tamer I. Khayal sold 3,142 shares of the company’s stock in a transaction that occurred on Monday, January 23rd. The stock was sold at an average price of $65.07, for a total transaction of $204,449.94. Following the sale, the insider now directly owns 1,300 shares of the company’s stock, valued at approximately $84,591. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

TransMedics Group Price Performance

TMDX stock traded down $0.46 during trading on Wednesday, reaching $66.97. 250,699 shares of the company were exchanged, compared to its average volume of 333,119. The company has a 50-day moving average of $59.59 and a two-hundred day moving average of $50.37. The company has a market capitalization of $2.14 billion, a price-to-earnings ratio of -44.91 and a beta of 1.58. TransMedics Group, Inc. has a twelve month low of $10.00 and a twelve month high of $68.43. The company has a debt-to-equity ratio of 0.31, a current ratio of 12.11 and a quick ratio of 11.21.

TransMedics Group (NASDAQ:TMDX – Get Rating) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.15. TransMedics Group had a negative net margin of 58.78% and a negative return on equity of 46.03%. The business had revenue of $25.68 million during the quarter, compared to analysts’ expectations of $18.96 million. As a group, equities analysts predict that TransMedics Group, Inc. will post -1.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. increased its position in TransMedics Group by 16.1% in the 3rd quarter. BlackRock Inc. now owns 2,198,654 shares of the company’s stock valued at $91,771,000 after acquiring an additional 304,600 shares during the period. Vanguard Group Inc. increased its position in TransMedics Group by 14.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,644,691 shares of the company’s stock valued at $68,650,000 after acquiring an additional 208,377 shares during the period. Lord Abbett & CO. LLC acquired a new position in TransMedics Group in the 3rd quarter valued at approximately $32,227,000. State Street Corp increased its position in TransMedics Group by 5.6% in the 3rd quarter. State Street Corp now owns 694,142 shares of the company’s stock valued at $28,973,000 after acquiring an additional 36,716 shares during the period. Finally, Bellevue Group AG increased its position in TransMedics Group by 12.7% in the 3rd quarter. Bellevue Group AG now owns 653,814 shares of the company’s stock valued at $27,290,000 after acquiring an additional 73,927 shares during the period. 88.58% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TMDX has been the subject of a number of recent analyst reports. Morgan Stanley upped their price target on shares of TransMedics Group from $54.00 to $63.00 and gave the stock an “equal weight” rating in a report on Friday, January 6th. Canaccord Genuity Group upped their price objective on shares of TransMedics Group from $58.00 to $63.00 and gave the stock a “buy” rating in a research report on Friday, November 4th. Finally, Cowen upped their price objective on shares of TransMedics Group from $60.00 to $70.00 in a research report on Friday, December 16th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, TransMedics Group presently has an average rating of “Moderate Buy” and a consensus target price of $53.29.

TransMedics Group Company Profile

(Get Rating)

TransMedics Group, Inc operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.